HealthBusiness
Moderna Surges After mRNA Cancer Treatment Passes Trial
Moderna and Merck announce their mRNA-based cancer vaccine intismeran met key endpoints in a Phase 3 melanoma trial, sending Moderna shares up over 120%.
—6 min read
Tag
4 articles
Moderna and Merck announce their mRNA-based cancer vaccine intismeran met key endpoints in a Phase 3 melanoma trial, sending Moderna shares up over 120%.
A nationwide shortage of chemotherapy drug ifosfamide is forcing US doctors to ration supplies and seek alternatives, exposing supply chain flaws.
GSK announces its largest-ever acquisition, buying US cancer biotech Nuvalent for $10.6 billion in a major oncology push under new CEO Luke Miels.
A new experimental pill nearly doubles survival for advanced pancreatic cancer patients, targeting the long-undruggable KRAS mutation.